1.Correlation study on mesenteric fat and disease behavior in patients of Crohn's disease
Xiaolong GE ; Rongpan BAI ; Weilin QI ; Wei LIU ; Yan WU ; Haili XU ; Lingna YE ; Qian CAO ; Wei ZHOU
Chinese Journal of General Surgery 2023;38(7):521-525
Objective:To analyze the relationship between mesenteric fat or creeping fat and bowel stricture or penetrating disease of Crohn's disease (CD).Methods:Clinical data of 101 CD patients undergoing bowel surgery at Department of General Surgery in our hospital between Mar 2021 and Dec 2021 were retrospectively analyzed. The characteristics of mesenteric fat, creeping fat, luminal cross-section diameter, and the intestinal stricture index were analyzed. The Spearman correlation analysis was used to evaluate the correlation between disease behavior and mesenteric fat score or creeping fat score.Results:Totally 101 CD patients were enrolled, with 68 stricturing diseases and 33 penetrating diseases. CD patients with stricturing diseases had higher score of mesenteric disease activity index (4.6±1.9 vs. 3.7±2.0, t=2.212, P=0.029) and creeping fat index (4.2±2.0 vs. 2.9±1.6, t=3.154, P=0.002) than those in patients with penetrating diseases. The mesenteric fat and creeping fat score positively correlated with the intestinal stricture index, C-reactive protein, and fecal calprotectin, and negatively correlated with minimum luminal cross-section diameter. Conclusion:The higher score of mesenteric fat and creeping fat were observed in CD patients with stricturing disease, which were associated with intestinal stricture index and inflammation status.
2.A case of Crohn′s disease complicated with hepatic tuberculosis during the treatment of biologics
Yipeng PAN ; Jing LIU ; Lingna YE ; Qian CAO
Chinese Journal of Inflammatory Bowel Diseases 2023;07(3):307-309
We report a case of Crohn′s disease complicated by hepatic tuberculosis during the treatment of infliximab. Reporting this rare case aims to make clinicians better understand hepatic tuberculosis, emphasize the proactive screening for tuberculosis, and also raise awareness of extrapulmonary tuberculosis in patients with inflammatory bowel disease during the treatment of biologics.
3.Diagnosis and therapy for a case of Crohn′s disease complicated with deep vein thrombosis and Guillain-Barre syndrome by the cooperation of multidisciplinary team
Chenfei TAN ; Yating YANG ; Lingna YE ; Min GAO ; Qian CAO
Chinese Journal of Inflammatory Bowel Diseases 2023;07(4):371-374
This article reports a rare Crohn′s disease (CD) case complicated with deep vein thrombosis and Guillain-Barre syndrome (GBS). Through the diagnosis and treatment of the multidisciplinary team, the condition of patient is relieved with no recurrence. Prevention of venous thromboembolism, rare extraintestinal manifestations and rare side adverse of anti-tumor necrosis factor-α monoclonal antibodies and their mechanisms in CD patients were discussed for reference.
4.A case of Crohn′s disease complicated with hepatic tuberculosis during the treatment of biologics
Yipeng PAN ; Jing LIU ; Lingna YE ; Qian CAO
Chinese Journal of Inflammatory Bowel Diseases 2023;07(3):307-309
We report a case of Crohn′s disease complicated by hepatic tuberculosis during the treatment of infliximab. Reporting this rare case aims to make clinicians better understand hepatic tuberculosis, emphasize the proactive screening for tuberculosis, and also raise awareness of extrapulmonary tuberculosis in patients with inflammatory bowel disease during the treatment of biologics.
5.Diagnosis and therapy for a case of Crohn′s disease complicated with deep vein thrombosis and Guillain-Barre syndrome by the cooperation of multidisciplinary team
Chenfei TAN ; Yating YANG ; Lingna YE ; Min GAO ; Qian CAO
Chinese Journal of Inflammatory Bowel Diseases 2023;07(4):371-374
This article reports a rare Crohn′s disease (CD) case complicated with deep vein thrombosis and Guillain-Barre syndrome (GBS). Through the diagnosis and treatment of the multidisciplinary team, the condition of patient is relieved with no recurrence. Prevention of venous thromboembolism, rare extraintestinal manifestations and rare side adverse of anti-tumor necrosis factor-α monoclonal antibodies and their mechanisms in CD patients were discussed for reference.
6.Rrisk factors, pathogenic bacteria and drug resistance of postoperative surgical site infection in patients with Crohn's disease
Xiaolong GE ; Weilin QI ; Wei LIU ; Haili XU ; Lingna YE ; Qian CAO ; Wei ZHOU
Chinese Journal of General Surgery 2021;36(7):520-524
Objective:To analyze the risk factors for postoperative surgical site infections (SSIs) in patients with Crohn's disease (CD).Methods:This retrospective observational study included CD patients undergoing bowel resection between July 2015 and July 2018. The prevalence and risk factors of SSIs were evaluated. The microbiological evaluation from patients with SSIs was performed by bacterial culture and drug sensitivity test.Results:There were 66 patients suffering SSIs, with 41 incisional SSIs and 32 organ/space SSIs. Multivariate analysis identified the preoperative infliximab therapy ( OR 2.338,95% CI 1.192-4.587, P=0.013), laparoscopic surgery ( OR 0.460,95% CI 0.226-0.936, P=0.013), and preoperative white blood cell ( OR 2.008,95% CI 1.018-3.961, P=0.044) as independent factors for SSIs. Fifty-nine strains of pathogenic bacteria were detected in 66 cases of CD combined with SSIs, including 36 strains of gram-negative bacteria, 5 strains of gram-positive bacteria, and 2 strains of fungi. Escherichia coli and Klebsiella pneumoniae were main G - bacteria, with high resistance to common used antibiotics. Enterococcus faecalis and Enterococcus faecium were main G -. 62.1% of the SSIs grew extended-spectrum β-lactamase (ESBL)-producing pathogens in their bacteria cultures and 37.9% grew non-ESBL microbes. Conclusion:The incidence of SSIs was higher in CD patients. Preoperative infliximab therapy, preoperative white blood cell, and laparoscopic surgery were predictors of SSIs.
7.Analysis of adverse effects of infliximab treatment in 486 patients with Crohn's disease
Kan WANG ; Lingna YE ; Yipeng PAN ; Weili LIU ; Qian CAO
Chinese Journal of Digestion 2019;39(8):555-561
Objective To assess the safety of infliximab (IFX) treatment in patients with Crohn's disease(CD).Methods From January 2009 to May 2018,at inflammatory bowel disease (IBD) center of Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University,486 CD patients received the treatment of IFX were enrolled and their clinical data were collected.Univariate and multivariate regression of binary logistic were performed for statistical analysis.Results The median follow-up duration was 31.1 months (12.0 months to 40.0 months).The median duration of IFX therapy was 13.0 months (7.0 months to 21.0 months).Among 486 patients,98 (20.16%) patients reported adverse effects,and 12 (2.47%) patients discontinued the therapy because of adverse effects.Acute infusion reaction was the most common adverse effect in CD patients who received IFX treatment accounting for 41.84% (41/98) of all the adverse effects,and the incidence was 8.44%.Thirty-nine patients had mild and moderate infusion reaction,and all improved after symptomatic treatment (eight patients discontinued IFX therapy because of recurrent infusion reaction).Two patients developed severe infusion reaction as allergic shock,and both relieved after emergency rescue.Four patients developed late-phase allergic reactions.Among 486 patients,39 (8.02%) patients had infections,including infections of Clostridium difficile,cytomegalovirus,herpeszoster virus,Mycobacterium tuberculosis,and other opportunistic pathogens.There was no cases of infection related death.Thirty-six patients continued with IFX treatment after infection controlled.Among 486 patients,14 (2.88%) patients had severe infection,and all the cases improved after anti-infection treatment.Twenty-seven CD patients with hepatitis B virus (HBV) infection received anti-viral treatments,no active HBV infection was observed.Colon adenocarcinoma was found in one patient under colonoscopy at 22 months after discontinuation of IFX therapy.There were six patients with the history of benign tumors,and no evidence of recurrence,progress or malignancy during treatment.In terms of other rare adverse effects in 486 patients,there were eight (1.64%) patients with liver function injury,two (0.41%) patients with anemia,one (0.21%) patient with peripheral neuropathy,and four (0.82%) patients with skin lesion.Prolonged duration of IFX therapy,without combination of immune-suppressors and with increased baseline body mass index (BMI) were the risk factors of acute infusion reactions.Prolonged duration of IFX therapy and with low baseline albumin level were the risk factors of infections.Conclusions IFX is generally safe as the treatment for CD patients,and its adverse effects can be clinically controlled.Screening before therapy and monitoring during therapy may reduce the risks of adverse effects.
8.Simultaneous Determination of Naringin and Neohesperidin in Weitong Pills by HPLC
Lingna PENG ; Ye DING ; Hui SUN ; Wenli LI ; Jiangnan LUO
China Pharmacist 2017;20(6):1112-1114
Objective: To establish a method for the content determination of naringin and neohesperidin in Weitong pills.Methods: An HPLC method was adopted.The determination was performed on an Agilent TC-C18 column with the mobile phase consisting of acetonitrile-water(20∶80)at the flow rate of 1.0 ml·min-1.The detection wavelength was set at 283nm.The column temperature was 30 ℃.Results: Naringin and neohesperidin respectively within the concentration range of 0.027-4.552 μg (r=0.999 9) and 0.029-4.016 μg(r=0.999 8) had good linear relationship with the peak area, the average recovery was 102.19% and 103.60%,and the RSD was 2.88% and 1.79%(n=9), respectively. Conclusion: The method is simple,accurate and reproducible, and suitable for the content determination of naringin and neohesperidin in Weitong pills.
9.Practice and experience of group therapy in improving the subjective well-being of elderly patients with long-term hospitalization
Min ZHAO ; Ping YE ; Shuqi HU ; Lingna GU ; Jianhong WU ; Dingmei SHI
Chinese Journal of Modern Nursing 2017;23(8):1102-1104
Objective To investigate the application effect of group therapy in improving the subjective well-being (SWB) of elderly patients with long-term hospitalization. Methods Totally 100 cases of elderly patients admitted in geriatric ward of Ningbo First Hospital for long-time were selected. Newfoundland scale of happiness (MUNSH) scale and the negative life events questionnaire were used to investigate elderly inpatients, and patients with MUNSH ≤12 points received group therapy. Patients were divided into several groups to receive the intervention according to the negative life events. One year after intervention,patients receiving group therapy were evaluated again by using MUNSH scale to evaluate the intervention effect. Results Among 100 elderly patients,there were 32 cases of high SWB,3 cases of low SWB,and 65 cases of medium SWB. 53 cases of patients had sleep disorders,and 62.26% of them had low SWB. After intervention,the scores of negative experience and emotion of elderly patients were lower than those before intervention (P<0.05);the scores of positive emotion and positive experience and the total MUNSH score were higher than those before intervention (P < 0.05). Conclusions According to the different influencing factors,group interventions can significantly improve the SWB level of elderly patients with long-term hospitalization,so as to improve their quality of life.
10.Determination of Soluble Heavy Metals in Baizi Yangxin Tablets by Inductively Coupled Plasma Mass Spectrometry with Bionic Extraction and Microwave Digestion Technology
Qiutao JIANG ; Li ZENG ; Jie MA ; Lingna PENG ; Wenli LI ; Ye DING ; Jie LI
Chinese Journal of Analytical Chemistry 2016;44(6):979-983
Baizi Yangxin tablets are common Chinese medicine used for the treatment of heart palpitations, insomnia and irritable forgetful. To evaluate the total amount of heavy metals evaluation, artificial gastric juice was used as juice samples and the extracted soluble heavy metals were extracted by microwave digestion technology. An analytical method of bionic extraction microwave digestion with inductively coupled plasma mass spectrometry ( ICP-MS ) was established for the determination of trace metals, such as Co, Cr, Cu, Ba, Cd, Mn, Ni, Pb, Hg, Sr and Zn, in 18 batches of Baizi Yangxin tablets. The correlation coefficient of linear regression equation for different elements ranged from 0. 9989 to 1. 0000, the detection limit was 0. 19-5. 6 μg / L, and the repeatability of the method was less than 6. 2% , the precision of the RSD value was less than 5. 6% , and the recovery rate was 87. 7% -101. 9% . According to “the standard of the heavy metal in the standard of import and export of medicinal plants and preparations”, the contents of Cd, Cu and Pb in the 18 batches were not exceed the standard, but the Hg content (7. 68 mg / kg) exceeded the standard value. The bionic extraction-ICP-MS method provide a reference basis for the safety of the proprietary Chinese medicine's study.

Result Analysis
Print
Save
E-mail